SEC Form 4 · accession 0001609351-19-000015
Spark Therapeutics, Inc. · ONCE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Federico Mingozzi
Officer — Chief Scientific Officer
Period of report
Jan 15, 2019
Accepted (ET)
Jan 17, 2019 · 9:45 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001609351
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $42.73 | Jan 15, 2019 | A | 35,000 | A | — | Jan 15, 2029 | Common Stock | 35,000 | 35,000 | D |
| Restricted Stock UnitsF2,F3 | — | Jan 15, 2019 | A | 10,000 | A | — | — | Common Stock | 10,000 | 10,000 | D |
Explanation of responses
- F125% vests January 15, 2020 and the remainder vests in equal annual installments over the following three years.
- F2Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics, Inc. common stock.
- F3The restricted stock units vest in four equal annual installments beginning January 15, 2020. Vested shares will be delivered to the reporting person annually on the vesting date.